Effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibition on endothelial dysfunction, bioavailability of tetrahydrobiopterin (BH4) and functional regulation of endothelial nitric oxide synthase (eNOS) in human heart failure

Belfast Health and Social Care Trust (UK)0 个研究点目标入组 60 人开始时间: 2008年10月27日最近更新: 2016年10月17日

适应症

试验速览

暂无简介。

•1. Both males and females, over 18 years of age
•2. Diagnosis of heart failure with an ejection fraction less than 35% determined by 2D echocardiography. Patients will be typically receiving maximal therapy for treatment of heart failure, including loop diuretics, angiotensin converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers and spironolactone.
•3. Patients must also be able to give informed consent, and to attend for follow up appointments

•1. History of diabetes mellitus (fasting glucose greater than 7 mmol/L) or uncontrolled hypertension (blood pressure [BP] greater than 140/90 mmHg) or are receiving the thienopyridine derivative clopidogrel
•2. Abnormal liver function (defined as aspartate aminotransferase [AST] or alanine aminotransferase [ALT] greater than three times upper limit of normal) or have had a previous documented adverse reaction to statin therapy or hypersensitivity to simvastatin or any of the excipients
•3. Pregnant or lactating
•4. Any patient who has an adverse reaction to statin therapy following initiation of treatment
•5. Patients taking potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, human immunodeficiency virus [HIV] protease inhibitors, erythromycin, clarithromycin)
•6. Patients taking cyclosporin, gemfibrozil or greater than 1 g/day niacin

发起方

Belfast Health and Social Care Trust (UK)